Skip to content
sellWeak cluster of 910b5-1 plan

Jonathan Lin sold $613k of EQIX

Chief Business Officer at EQUINIX INC. 635 shares at an average of $965.71, traded Mar 12, 2026, filed Mar 13, 2026.

Warning score
15
Value
$613k
635 shares
Holdings after
10,788
-6% from before
From 52-week low
+35%
low $715.18, close $962.09
From 52-week high
-0%
high $964.85, as of Mar 12, 2026

Score components

  • Role
    Officer
    +15
  • Trade size
    $613k at market
    +20
  • Share of holdings sold
    Sold 5.6% of holdings
    0
  • Cluster
    9 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

EQIXOct 9, 2026 · close 1,026
Since filing Mar 13, 2026: +6.8%SPY +18.5% · excess -11.7%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001101239-26-000062, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Mar 11, 2026MOption exercise
Common Stock10b5-1
+635$0.00$011,423Mar 13, 2026
Mar 12, 2026SOpen-market sale
Common Stock10b5-1
-18$958.00$17k11,405Mar 13, 2026
Mar 12, 2026SOpen-market sale
Common Stock10b5-1
-31$959.00$30k11,374Mar 13, 2026
Mar 12, 2026SOpen-market sale
Common Stock10b5-1
-22$960.13$21k11,352Mar 13, 2026
Mar 12, 2026SOpen-market sale
Common Stock10b5-1
-52$961.17$50k11,300Mar 13, 2026
Mar 12, 2026SOpen-market sale
Common Stock10b5-1
-42$962.60$40k11,258Mar 13, 2026
Mar 12, 2026SOpen-market sale
Common Stock10b5-1
-18$963.72$17k11,240Mar 13, 2026
Mar 12, 2026SOpen-market sale
Common Stock10b5-1
-37$965.34$36k11,203Mar 13, 2026
Mar 12, 2026SOpen-market sale
Common Stock10b5-1
-41$966.16$40k11,162Mar 13, 2026
Mar 12, 2026SOpen-market sale
Common Stock10b5-1
-187$967.44$181k10,975Mar 13, 2026
Mar 12, 2026SOpen-market sale
Common Stock10b5-1
-115$968.30$111k10,860Mar 13, 2026
Mar 12, 2026SOpen-market sale
Common Stock10b5-1
-72$969.14$70k10,788Mar 13, 2026
Mar 11, 2026AGrant or award
Restricted Stock Unitderivative10b5-1
+635$0.00$0635Mar 13, 2026
Mar 11, 2026MOption exercise
Restricted Stock Unitderivative10b5-1
-635$0.00$00Mar 13, 2026

Related signals

Other insiders at EQUINIX INC and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
34Weak
EQIXsell
EQUINIX INC
Michael Shane Paladin
Chief Customer & Rev Officer
$318k
307 shares
-11%
0Weak
EQIXsell10b5-1
EQUINIX INC
Michael Shane Paladin
Chief Customer & Rev Officer
$206k
203 shares
-7%
45Moderate
EQIXsell 510b5-1
EQUINIX INC
Brandi Galvin Morandi
Chief People Officer
$4.0M
3,726 shares
-38%
6Weak
EQIXsell 510b5-1
EQUINIX INC
Raouf Abdel
EVP, Global Operations
$168k
158 shares
-3%
35Weak
EQIXsell 510b5-1
EQUINIX INC
Adaire Fox-Martin
CEO and President
$3.1M
2,935 shares
-12%
6Weak
EQIXsell 510b5-1
EQUINIX INC
Jonathan Lin
Chief Business Officer
$159k
150 shares
-1%
4Weak
EQIXsell 510b5-1
EQUINIX INC
Kurt Pletcher
Chief Legal Officer
$84k
79 shares
-2%
65Notable
EQIXsell 5
EQUINIX INC
Raouf Abdel
EVP, Global Operations
$2.2M
2,040 shares
-26%
21Weak
EQIXsell 310b5-1
EQUINIX INC
Christopher B Paisley
director
$133k
125 shares
-1%
58Moderate
EQIXsell 2
EQUINIX INC
Charles J Meyers
director, other
$5.7M
5,224 shares
-41%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.